Finding Drugs, Foiling Disease

  1. Home
  2. Industry
  3. Finding Drugs, Foiling Disease

Innovation in your Inbox. Sign up for the CRI’s Newsletter

  • This field is for validation purposes and should be left unchanged.
Pathways To Partnership

Partner with Northeastern.

Minimize Risk. Maximize Insights. Multiply Results.

Purposeful Partnering for Customized Solutions

Pathways to Partnership events are panel discussions aimed at cultivating connections between Northeastern research laboratories and R&D professionals. During these events, Northeastern panelists outline research capabilities and field questions thereby stimulating partnering opportunities for customized solutions.

Past Panel

Finding Drugs, Foiling Disease

Powering Northeastern’s drug discovery agenda, panelists represent expertise in:

Cancer therapies | Cardiovascular diseases | Drug tolerance | Regenerative medicine | CNS diseases | Drug delivery | Antibiotics | Computational modeling | Mass spectrometry | Drug addiction

Event Details

September 25, 2017
Raytheon Amphitheater, Northeastern University

  • 2:00 – 3:00 | Panel Discussion
  • 3:00 – 4:00 | Venture & Project Spotlight
  • 4:00 – 4:30 | Networking
Diomedes Logothetis

Northeastern has the pharmacological, biochemical, and biophysical knowledge to make the molecules that will become the next generation of drugs.
 ~ Diomedes Logothetis, Northeastern University

Panelists

Jeffrey Agar

The Agar Group

Mansoor Amiji

Biomaterials and Advanced Nano-Delivery Systems

Joel Bresler | Moderator

Center for Research Innovation

Rebecca Carrier

Advanced Drug Delivery Research Laboratory

Kim Lewis

Antimicrobial Discovery Center

Diomedes Logothetis

Pharmaceutical Sciences

Ganesh Thakur

Thakur Laboratory

Compelling Technologies

Retinal Regeneration

Discover a natural matrix that enhances retinal cellular therapies for visual restoration.

Nested Delivery

Target macrophage for safe and robust drug, gene, and vaccine delivery.

Neurological Therapeutic

Treat CNS diseases at the source by utilizing precision gene therapy with intranasal delivery.

Venture & Project Presenters

Raymond Booth
Dr. Raymond Booth

Dr. Raymond Booth

Scientific Founder and Chief Scientist, Seropeutics | Professor, Pharmaceutical Sciences

Seropeutics develops efficacious therapies addressing the needs of Fragile X syndrome, the most common monogenetic form of autism, and has identified two promising candidates, SERx – 519 and SERx – 480 (preclinical development stage).

Raymond Booth
Ahmed Busnaina
Dr. Ahmed Busnaina

Dr. Ahmed Busnaina

Director, Center for High-rate Nanomanufacturing | Distinguished Professor and Chair, College of Engineering

The Nanoscale Offset Printing System (NanoOps), developed by the Center for High-rate Nanomanufacturing and Milara Inc., represents the ability to print a sweeping array of pharma products of diverse composition with efficient precision.

Ahmed Busnaina
Shashi Murthy
Dr. Shashi Murthy

Dr. Shashi Murthy

Founder, Flaskworks | Professor, College of Engineering

Flaskworks develops modular, closed, and disposable systems for the manufacture of dendritic cells and stimulation and expansion of T cells for the rapidly growing immuno-oncology and dendritic cell-based vaccine markets.

Shashi Murthy
Srinivas Sridhar
Dr. Srinivas Sridhar

Dr. Srinivas Sridhar

Founder, TheraNano | Distinguished Professor, College of Science

TheraNano has a strong pipeline of nanomedicine and medical imaging technologies, including: a platform for sustained delivery of chemotherapeutics; nanoformulations of PARP and other inhibitors for cancer therapy; and, a quantitative MRI method utilizing magnetic nanoparticles to obtain unprecedented vascular images.

Srinivas Sridhar
Jonathan Tilly
Dr. Jonathan Tilly

Dr. Jonathan Tilly

Distinguished Professor, College of Science

The Tilly Lab improves women’s reproductive health and overcomes infertility by translating discoveries made through cellular, molecular, genetic, and epigenetic studies of female germ cells. Findings have opened regenerative avenues for overcoming infertility and preventing ovarian failure while also sparking research targeting mitochondria and cellular energy pathways.

Jonathan Tilly
Dori Woods
Dr. Dori Woods

Dr. Dori Woods

Director, Woods Lab | Associate Professor, College of Science

Focusing on female reproduction, the Woods Lab emphasizes new strategies to delay or prevent ovarian failure. Areas of investigation include: the targeted specification of multiple ovarian cell lineages from stem cells; the interaction between ovarian soma and adult ovary germline; the contribution of germline and soma to ovarian failure; and, bioengineering an ‘artificial’ ovary for generating functional eggs from stem cells.

Dori Woods
Menu